Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Declines By 53.5%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totaling 8,093 shares, a decrease of 53.5% from the July 15th total of 17,399 shares. Approximately 0.6% of the company’s stock are sold short. Based on an average daily volume of 14,409 shares, the short-interest ratio is currently 0.6 days.

Global X Genomics & Biotechnology ETF Trading Down 1.2%

Shares of GNOM stock traded down $0.70 on Friday, hitting $58.36. 11,784 shares of the stock were exchanged, compared to its average volume of 15,683. Global X Genomics & Biotechnology ETF has a fifty-two week low of $36.00 and a fifty-two week high of $59.99. The business has a 50-day moving average of $54.86 and a 200 day moving average of $49.06. The firm has a market capitalization of $85.21 million, a P/E ratio of -24.94 and a beta of 1.17.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently announced a dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were issued a dividend of $0.0579 per share. The ex-dividend date was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio is presently -27.35%.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its holdings in Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after buying an additional 48,394 shares during the last quarter. Sei Investments Co. grew its holdings in Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after purchasing an additional 12,105 shares during the period. Jane Street Group LLC increased its position in Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after buying an additional 10,308 shares during the last quarter. Wealth Management Partners LLC acquired a new position in Global X Genomics & Biotechnology ETF during the first quarter worth approximately $244,000. Finally, Smartleaf Asset Management LLC raised its stake in Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after buying an additional 4,615 shares during the period. 56.95% of the stock is owned by institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.